Oncology
GenFleet and BeiGene partner for Phase Ib/II lymphoma treatment trial
GenFleet Therapeutics has signed a clinical trial collaboration and supply agreement with BeiGene Switzerland to commence a Phase Ib/II clinical…
InnoCare doses first subject in Phase Ib NSCLC combination treatment trial
InnoCare Pharma has dosed the first subject in a Phase Ib clinical trial assessing a combination its ICP-189 plus ArriVent…
Bristol Myers Squibb’s Phase III trial of KRAZATI meets endpoints
Bristol Myers Squibb (BMS) has announced that its Phase III KRYSTAL-12 clinical trial of KRAZATI (adagrasib) for treating non-small cell…
Novocure’s TTFields device slows metastasis in NSCLC
Novocure’s Tumor Treating Fields (TTFields) therapy met its primary endpoint in the Phase III METIS trial by slowing the progression…
Iambic begins dosing in trial of IAM1363 for HER2-driven cancer
Iambic Therapeutics has initiated the dosing of the first subject in its Phase I/Ib clinical trial of IAM1363, a novel…
Immuneering doses first subject in Phase I/IIa solid tumour trial
Immuneering has dosed the first subject in its Phase I/IIa clinical trial of IMM-6-415 for the treatment of advanced solid…
Regeneron hit with FDA rejection for blood cancer therapy
The US Food and Drug Administration (FDA) has rejected Regeneron Pharmaceutical’s approval application for odronextamab in two forms of lymphoma,…
Edgewood secures $20m in Series A for clinical development of cancer therapy
Massachusetts-based company Edgewood Oncology has raised $20m in Series A to advance the clinical development of its lead cancer therapy…
Ovarian cancer: four drug trials to watch
Most patients with ovarian cancer are diagnosed at late stage as symptoms at early stages are minimal making it difficult…
Innate shelves lacutamab monotherapy plans in peripheral T cell lymphoma
Innate has dropped plans to evaluate lacutamab as a monotherapy in KIR3DL2-expressing refractory/relapsing peripheral T cell lymphoma (r/r PTCL) following…